Centene (CNC) Q3 2026 Earnings Call Transcript

Centene reported Q3 adjusted diluted EPS of $0.58, above its expectations, and raised 2026 adjusted EPS guidance to greater than $5.20 from a previous floor of $4.80; revenue was $45.1 billion, up 0.5%. Management expects Medicare Advantage to reach breakeven in 2026, a year ahead of its prior plan, and raised its 2026 Marketplace pretax margin outlook to the top of its 4.5%–5.0% range. Offsetting risks include projected Medicaid membership declines and 2027 headwinds from eligibility changes; Centene also repurchased $1.1 billion of senior notes, bringing reported total debt to $15.0 billion.

Analysis

CNC’s beat improves near-term confidence, but the quality of the 2027 earnings bridge matters more than the raised 2026 number. Management’s $4.70 jump-off explicitly strips out $0.50 of benefits not expected to recur; the assertion that 2027 growth could exceed even 2026 guidance is therefore a testable claim, not yet an underwritten run rate. The key swing factor is Medicaid rate adequacy versus acuity as eligibility changes roll through. More gradual disenrollment and prospective state rate adjustments would reduce the risk of a margin squeeze; faster exits or delayed rate catch-up could reverse the recovery even as membership falls. Watch the January rate resets and February guidance for evidence, not verbal optimism.

Near term, earnings momentum and debt retirement can support sentiment. Over 1–3 months, AEP enrollment, Marketplace retention/pricing, and Medicaid rate disclosures determine whether that momentum carries. Over 6–18 months, MA’s move from breakeven toward profit and durable SG&A savings are upside levers, while lower MA membership, Medicaid exits, and the expected PDP margin normalization constrain growth. The 2026 Marketplace and PDP outperformance may prove partly transient; do not extrapolate it. Nor should the reported food-benefit claims association be treated as proven, scalable savings without independent validation. Overall, constructive but not a clean re-rating signal: the market may be underweight execution progress and overweight regulatory headlines, yet the 2027 bridge remains insufficiently quantified.

Key Decisions for Investors

• Avoid chasing the earnings reaction. Consider a staged CNC long only after AEP and the January Medicaid rate picture provide better visibility; keep exposure modest until the 2027 guide. The thesis is improving execution and debt reduction; it is falsified by guidance that implies 2027 EPS below the $4.70 baseline or materially weaker Medicaid HBR.
• Track the February 2027 guide for Medicaid HBR, rate updates versus acuity, MA membership/margins, and quantified SG&A savings. A favorable rate-to-acuity match and evidence that cost savings are recurring would support adding; delayed rate catch-up or adverse HBR progression argues for reducing exposure.
• Treat Marketplace/PDP margin upside as a potential normalization risk, not a recurring earnings multiple driver. Reassess if PDP approaches the stated 2%–3% target while Marketplace pricing or IDR-related reserves weaken; verify claims development and enrollment outcomes before crediting the 2026 uplift as durable.